Rowan Miller
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Chromatin Remodeling and Cancer, Endometrial and Cervical Cancer Treatments, Cancer Mechanisms and Therapy
Most-Cited Works
- → ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer(2020)464 cited
- → ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A(2016)379 cited
- → Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity(2013)363 cited
- → Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(2023)337 cited
- → Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group(2024)284 cited
- → Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non– BRCA1/2 -Mutant Cancers(2020)130 cited
- → Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data(2019)117 cited
- → Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines(2016)108 cited
- → Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors(2023)107 cited
- → First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors(2022)90 cited